Vyas S P, Sihorkar V
Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, India.
J Clin Pharm Ther. 1999 Aug;24(4):259-72. doi: 10.1046/j.1365-2710.1999.00226.x.
Infection of human stomach by Helicobacter pylori, a gram negative spiral bacterium first isolated in 1983 from a patient with chronic active gastritis (1), causes nearly all duodenal ulcers and most gastric ulcers and is associated with an increased risk of gastric adenocarcinoma (2). Current therapies for gastric infections include combination triple or quadruple therapy of antimicrobial and/or antiulcer agents for eradication of H. pylori infection (3). Development of the resistant strains and ecological niche (habitant) of the bacteria may cause relapse after the termination of the therapy. However, if effective, the high cost, difficulty of patient compliance and risk of selection for resistant strains make these therapeutic regimens impractical on a large scale, though effective on the laboratory trial stages. Studies of the pathogenesis of H. pylori have led to the identification of bacterial antigens and adherin proteins as candidates for inclusion as novel vaccines against these diseases (4-7). Both prophylactic and therapeutic vaccination have been demonstrated in animal models of H. pylori infection (8-10).
幽门螺杆菌是一种革兰氏阴性螺旋菌，于1983年首次从一名患有慢性活动性胃炎的患者中分离出来(1)。幽门螺杆菌感染人类胃部会导致几乎所有的十二指肠溃疡和大多数胃溃疡，并增加患胃腺癌的风险(2)。目前治疗胃部感染的方法包括使用抗菌和/或抗溃疡药物进行三联或四联联合治疗，以根除幽门螺杆菌感染(3)。细菌耐药菌株的出现和生态位（栖息地）可能导致治疗结束后复发。然而，如果有效，高昂的成本、患者依从性的困难以及耐药菌株选择的风险使得这些治疗方案虽然在实验室试验阶段有效，但在大规模应用时不切实际。对幽门螺杆菌发病机制的研究已导致鉴定出细菌抗原和粘附蛋白，作为新型抗这些疾病疫苗的候选物(4-7)。在幽门螺杆菌感染的动物模型中已证实了预防性和治疗性疫苗接种(8-10)。
